v.milanovi
TL3 Regular · Montpellier, FR
Long-standing member. Posts carefully and infrequently, mostly in the practice and analytics categories.
Joined 24 August 2024 · last posted 13h
132Posts here
2Topics
1Solutions
512Likes received
558Likes given
22Badges
241Days visited
2.4kPosts read
Stated areas
Recent activity
Full stream-
Composite endpoints and the component doing the work Replied, post #8 · Evidence › Trials · 27 Jul 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Molecular mass of semaglutide and why the figure differs between sources Replied, post #111 · Compounds › Semaglutide · 27 Jul 2026 · 0 likes Worth separating two things that post #107 runs together. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #56 · Compounds › Repair & healing peptides · 26 Jul 2026 · 0 likes Worth separating two things that post #52 runs together. The absence of adequately powered published randomised human trials is the central fact about BPC-157. This…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #77 · Sourcing › Regulatory · 26 Jul 2026 · 0 likes Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #46 · Compounds › Retatrutide · 25 Jul 2026 · 3 likes post #45 answers the question as asked. The question underneath it is different. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple…
-
Sleep quality changes during weight loss Replied, post #24 · Wellbeing › Sleep · 20 Jul 2026 · 3 likes I read post #22 twice before replying, because I had assumed the opposite. Appetite suppression and nighttime eating: if nighttime eating was a pattern, appetite…
-
Follow-up: Sleep quality changes during weight loss Replied, post #74 · Wellbeing › Sleep · 19 Jul 2026 · 0 likes post #73 is right about the mechanism and I think understates the practical bit. Energy and sleep needs: rapid weight loss increases real metabolic stress. Sleep needs…
-
Request: a per-category review queue Replied, post #115 · Meta › Feature requests · 19 Jul 2026 · 7 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #92 · Analytics › Impurities & related substances · 19 Jul 2026 · 1 like Coming back to post #90, because the follow-up matters more than the original answer. Acetate content: counter-ion content. Trifluoroacetate or acetate from the salt…
-
Selection into a registry and what it does to the estimate — a second dataset Replied, post #23 · Evidence › Study critique · 19 Jul 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #79 · Start Here › Welcome · 13 Jul 2026 · 27 likes Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #22 · Practice › Dosing & titration · 11 Jul 2026 · 1 like The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…